Radiopharmaceuticals

I began as a consultant for a clinical-stage biotechnology startup dedicated to improving cancer patients' lives through the development of innovative targeted radiopharmaceuticals based on camelid single domain antibody fragments.

While expanding and broadening its oncology portfolio, the business is moving its main product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive cancers.

Project management consulting, oversight strategy development, budget planning and management are among the services provided, with direct reporting lines to the head of clinical operations.